Sign inJoin waitlistJoin the waitlist

Ana Aparicio

Professor, Genitourinary Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
Keck Medicine of USC
1998–2001
Internal Medicine
UCLA David Geffen School of Medicine/UCLA Medical Center
1997–1998
Medical Oncology
1996–1997
Doctor of Medicine
1991–1995

Research

Epigenetics in human disease and prospects for epigenetic therapy
Review · Nature · 2004 · 2,317 citations
Platinum-based chemotherapy for variant castrate-resistant prostate cancer
Clinical Cancer Research · 2013 · First of 17 authors · Corresponding · 389 citations
Aggressive variants of castration-resistant prostate cancer
Review · Clinical Cancer Research · 2014 · 364 citations

Christopher Logothetis
51 papers
Paul Corn
42 papers
Patricia Troncoso
30 papers
Sumit Subudhi
28 papers
Brian Chapin
22 papers
EE
Eleni Efstathiou
22 papers
Shi-Ming Tu
14 papers
Chad Tang
13 papers
John Araujo
13 papers
Himisha Beltran
11 papers
Nizar Tannir
11 papers
Louis Pisters
10 papers

Grants

Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
National Cancer Institute · R01
Contact PI · $2.5M · University of Tx Md Anderson Can Ctr
2023–2028
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $9.3K · University of Southern California
2008–2009

Clinical trials

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2024–2027
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2020–2027
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2020–2026
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2016–2028